Clinical trials: Leanness
Individuals With Constitutional Thinness
Clinical Trial in Constitutional Thinness
The purpose of this study is to evaluate the molecular differences between a group of Constitutionally Thin (CT) subjects and a group of controls.
- Trial name
- NCT02004821
- Testing
- Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Cachexia
A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin
This study will examine whether a single dose of PF-05230901 is safe and well tolerated when given to healthy volunteers by injection under the skin. An additional objective is to measure the blood concentrations of PF-05230901.
- Trial name
- NCT01262690
- Testing
- PF-05230901
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cachexia
A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects
This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia.
- Trial name
- NCT05529849
- Testing
- TCMCB07
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Endevica Bio
Cachexia
Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
- Trial name
- NCT03392116
- Testing
- NGM120
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Cachexia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects
This study is the first administration of GSK2849466 in humans. This will be a single centre, randomized, double-blind, placebo-controlled study, to investigate the safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT01696604
- Testing
- GSK2849466
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo.
- Trial name
- NCT01669174
- Testing
- BYM338
- Where
- 9 sites in United States, Netherlands and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Cachexia
Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
GSK2881078 is a selective androgen receptor modulator (SARM) that is being evaluated for effects on muscle growth and strength in subjects with muscle wasting to improve their physical function.
- Trial name
- NCT02567773
- Testing
- GSK2881078, Itraconazole
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cachexia
A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers
This is a single-blind, randomized placebo-controlled, parallel study, where the study volunteers will be blinded to testosterone/placebo treatment.
- Trial name
- NCT01962454
- Testing
- Deuterated Water, Testosterone enanthate
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cachexia, Anorexia
Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers
Phase I study of Megace F will be conducted to investigate pharmacokinetics and safety compared to Megace OS. Phase I study divided into 3 parts written as belows.
- Trial name
- MGF (NCT01397214)
- Testing
- Megace F, Megace OS
- Where
- South Korea
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Cachexia
A Phase 1 Study of AV-380 in Healthy Subjects
This double-blinded, placebo-controlled, single ascending dose (SAD) study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in healthy subjects of a single dose of AV-380.
- Trial name
- NCT04815551
- Testing
- AV-380
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AVEO Pharmaceuticals, Inc.
Cachexia
Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)
The aim of this early phase two-part study was to compare the bioavailability (BA) pharmacokinetics (PK) and pharmacodynamics (PD) of racemic pindolol with the benzoate salt of the S-enantiomer of pindolol (ACM-001.1) and provide…
- Trial name
- NCT06028321
- Testing
- Part 1 Group 1 Regime A (ACM-001.1), Part 1 Group 2 Regimen C (Pindolol), Part 2 Group D (Pindolol)
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Actimed Therapeutics Ltd
Cachexia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses
This study is the first administration of GSK2881078 to humans. The intention of this study is to provide sufficient confidence in the safety of the molecule to inform progression to further repeat dose and proof of concept…
- Trial name
- NCT02045940
- Testing
- GSK2881078
- Where
- 2 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline